The PASTEUR Act of 2026 establishes a subscription-style contract program to incentivize the development and ensure the availability of novel antimicrobials against urgent threats while promoting their appropriate use.
Earl "Buddy" Carter
Representative
GA-1
The PASTEUR Act of 2026 aims to combat antimicrobial resistance by creating a subscription-style contract program to incentivize the research and development of new, life-saving antibiotics. This program will provide substantial annual payments to drug sponsors for ensuring the availability and appropriate use of eligible antimicrobials targeting urgent threats. The bill also establishes grants to promote stewardship programs in healthcare facilities and enhance national surveillance of resistance data.
PASTEUR Act Proposes $6 Billion 'Subscription Model' to Jumpstart New Antibiotics and Fight Superbugs by 2026.
The PASTEUR Act of 2026 is essentially trying to fix a broken business model in the world of medicine. Right now, pharmaceutical companies don't have much incentive to develop new antibiotics because, unlike a daily blood pressure pill, a good antibiotic is used sparingly and only for a short time. This bill changes the game by offering drug makers a 'subscription'—guaranteed annual payments between $75 million and $300 million—just to have effective, novel antimicrobials ready and available on the shelf. The goal is to ensure that when a 'superbug' hits, we actually have the tools to fight it.
The Subscription for Survival
Under this plan, the government isn't just buying pills; it’s buying readiness. If a company develops a drug that treats a high-priority threat listed by the CDC, they can apply for a 10-year contract (Section 3). The catch? The company has to keep the drug available, track how well it’s working against resistance, and follow strict rules on how it’s marketed. Think of it like a fire insurance policy for the nation’s medicine cabinet. For a patient with a drug-resistant infection, this could be the difference between a standard recovery and a life-threatening crisis. However, because the Secretary of HHS has significant leeway in 'scoring' which drugs get these lucrative contracts, there’s a medium level of vagueness regarding which companies will actually win these massive payouts.
Boosting the Front Lines
It’s not all about the big drug companies, though. The bill earmarks up to $390 million for grants targeting hospitals and nursing homes (Section 399PP2). These funds are designed to help facilities—especially those in rural areas or serving Tribal populations—better track how antibiotics are used and improve their 'stewardship' programs. For a nurse at a small-town clinic or a family member in a senior living facility, this means better data and smarter prescribing habits, which helps keep existing drugs effective for longer. It’s a ground-up approach to making sure we don't waste the medicine we already have.
The $6 Billion Question
While the public health benefits are clear, the price tag is substantial. The bill authorizes $6 billion in emergency funding for 2026 to get this off the ground. As a taxpayer, you’re essentially fronting the cash to de-risk the research for private companies. While the annual payments to these companies are reduced by the revenue they make from actual sales, the initial investment is a major commitment of public funds. There is also a natural skepticism to consider: with the pharmaceutical industry being a major player in policy circles, the structure of these guaranteed payments will require heavy oversight to ensure the public is getting a fair return on its $6 billion investment.